Drug Trial Radar · NCT06973629
Efficacy and Safety of MSC-NTF (NurOwn) in Participants With Early Symptomatic ALS and Moderate Disease Presentation in ALS (ENDURANCE STUDY)
Last checked: Nov 20, 2026Latest source record: May 22, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
200
Planned (sponsor's estimate)
Start
Jun 30, 2025
Primary completion
Nov 1, 2028
Study completion May 1, 2029
Sponsor
- Lead sponsor
- Brainstorm-Cell TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- May 15, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this two-part clinical trial is: 1\) to evaluate the safety and efficacy of Debamestrocel - MSC-NTF (NurOwn) compared to placebo in participants with early symptomatic ALS and moderate disease presentation in ALS; followed by 2) further evaluation by providing NurOwn to all participants in an open label extension period. Researchers will compare NurOwn to a placebo (a look-alike substance that contains no drug) to evaluate the efficacy of NurOwn compared to placebo in the treatment of participants with ALS. Participants will: Receive NurOwn or a placebo every 8 weeks for 24 weeks. After that, every participant will receive NurOwn every 8 weeks for an additional 24 weeks. They will visit the clinic approximately every 8 weeks for checkups and tests.
Conditions
- Amyotrophic Lateral Sclerosis (ALS)
- Amyotrophic Lateral Sclerosis
Interventions
Debamestrocel - MSC-NTF (NurOwn)Biological
MSC-NTF cells suspended in excipient Dulbecco Modified Eagle Medium (DMEM).
PlaceboBiological
Dulbecco Modified Eagle Medium (DMEM).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in the ALSFRS-R total score from baseline to Week 24Time frame: From baseline to Week 24
- Frequency and severity of adverse events including treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), death, abnormalities in laboratory evaluations, physical examinations, vital signs and electrocardiogram (ECG) assessmentsTime frame: From baseline to Week 48
Locations
15 sites in 1 country. Site status is shown where the registry gives one.
Barrow Neurological Institute
Phoenix, Arizona
University of California San Diego Medical Center
La Jolla, California
University of Southern California
Los Angeles, California
California Pacific Medical Center
San Francisco, California
University of California, San Francisco
San Francisco, California
University of Colorado Anschutz Medical Campus School of Medicine
Aurora, Colorado
Nova Southeastern University
Davie, Florida
Mayo Clinic
Jacksonville, Florida
University of South Florida
Tampa, Florida
Northwestern Medicine
Chicago, Illinois
Sean M. Healey & AMG Center For ALS At Massachusetts General Hospital
Boston, Massachusetts
University of Massachusetts Medical School
Worcester, Massachusetts
Mayo Clinic
Rochester, Minnesota
Providence ALS Center
Portland, Oregon
Temple University Of The Commonwealth System of Higher Education
Philadelphia, Pennsylvania
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.